The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19.
Expert Rev Anti Infect Ther
; : 1-9, 2024 Jan 30.
Article
in En
| MEDLINE
| ID: mdl-38288986
ABSTRACT
BACKGROUND:
The aim of this study was to assess the efficacy and safety of NRICM101 in hospitalized patients with COVID-19. RESEARCH DESIGN ANDMETHODS:
We conducted a retrospective study from 20 April 2021 to 8 July 2021, and evaluated the safety and outcomes (mortality, hospital stay, mechanical ventilation, oxygen support, diarrhea, serum potassium) in COVID-19 patients. Propensity score matching at a 12 ratio was performed to reduce confounding factors.RESULTS:
A total of 201 patients were analyzed. The experimental group (n = 67) received NRICM101 and standard care, while the control group (n = 134) received standard care alone. No significant differences were observed in mortality (10.4% vs. 14.2%), intubation (13.8% vs. 11%), time to intubation (10 vs. 11 days), mechanical ventilation days (0 vs. 9 days), or oxygen support duration (6 vs. 5 days). However, the experimental group had a shorter length of hospitalization (odds ratio = 0.12, p = 0.043) and fewer mechanical ventilation days (odds ratio = 0.068, p = 0.008) in initially severe cases, along with an increased diarrhea risk (p = 0.035).CONCLUSION:
NRICM101 did not reduce in-hospital mortality. However, it shortened the length of hospitalization and reduced mechanical ventilation days in initially severe cases. Further investigation is needed.
Full text:
1
Database:
MEDLINE
Traditional Medicines:
Medicinas_tradicionales_de_asia
/
Medicina_china
Type of study:
Observational_studies
/
Risk_factors_studies
Language:
En
Journal:
Expert Rev Anti Infect Ther
Year:
2024
Type:
Article
Affiliation country:
Taiwan